Abstract
BACKGROUND--Platelet activating factor (PAF) has been implicated in the pathogenesis of airway hyperresponsiveness in asthma. The purpose of this study was to evaluate the effects of a selective PAF antagonist (WEB 2086), given in doses known to antagonise the effects of inhaled PAF in human subjects, on allergen induced early and late asthmatic responses and on airway hyperresponsiveness. METHODS--Eight atopic, mildly asthmatic subjects were studied during a screening period and two treatment periods. During the screening period subjects inhaled an allergen to which they were known to be sensitised and the response was measured as the fall in the forced expired volume in one second (FEV1) to show the presence of early (0-1 h) and late (3-7 h) asthmatic responses. On another day the subjects inhaled allergen diluent. During the treatment periods subjects inhaled allergen after one week's pretreatment with WEB 2086 (100 mg three times a day) or placebo administered in a randomised, double blind, crossover fashion. Histamine airway responsiveness was measured 24 hours before and 24 hours after allergen and the results were expressed as the provocative concentration causing a 20% fall in FEV1 (PC20). RESULTS--The maximal early asthmatic response after allergen with placebo treatment was 18.4% (SE 4.4%) and with WEB 2086 18.9% (4.4%). The maximal late response with placebo treatment was 21.7% (5.3%) and with WEB 2086 21.2% (3.0%). The log difference (before and after allergen) in histamine PC20 was 0.35 (0.06) after placebo treatment and 0.30 (0.1) after WEB 2086. CONCLUSIONS--These results indicate that one week of treatment with an orally administered PAF antagonist (WEB 2086) does not attenuate allergen induced early or late responses or airway hyperresponsiveness.
Full text
PDFSelected References
These references are in PubMed. This may not be the complete list of references from this article.
- Abraham W. M., Stevenson J. S., Garrido R. A possible role for PAF in allergen-induced late responses: modification by a selective antagonist. J Appl Physiol (1985) 1989 May;66(5):2351–2357. doi: 10.1152/jappl.1989.66.5.2351. [DOI] [PubMed] [Google Scholar]
- Adamus W. S., Heuer H. O., Meade C. J., Schilling J. C. Inhibitory effects of the new PAF acether antagonist WEB-2086 on pharmacologic changes induced by PAF inhalation in human beings. Clin Pharmacol Ther. 1990 Apr;47(4):456–462. doi: 10.1038/clpt.1990.57. [DOI] [PubMed] [Google Scholar]
- Barnes P. J., Chung K. F., Page C. P. Platelet-activating factor as a mediator of allergic disease. J Allergy Clin Immunol. 1988 May;81(5 Pt 1):919–934. doi: 10.1016/0091-6749(88)90952-9. [DOI] [PubMed] [Google Scholar]
- Basran G. S., Page C. P., Paul W., Morley J. Platelet-activating factor: a possible mediator of the dual response to allergen? Clin Allergy. 1984 Jan;14(1):75–79. doi: 10.1111/j.1365-2222.1984.tb02193.x. [DOI] [PubMed] [Google Scholar]
- Beasley R. C., Featherstone R. L., Church M. K., Rafferty P., Varley J. G., Harris A., Robinson C., Holgate S. T. Effect of a thromboxane receptor antagonist on PGD2- and allergen-induced bronchoconstriction. J Appl Physiol (1985) 1989 Apr;66(4):1685–1693. doi: 10.1152/jappl.1989.66.4.1685. [DOI] [PubMed] [Google Scholar]
- Cartier A., Thomson N. C., Frith P. A., Roberts R., Hargreave F. E. Allergen-induced increase in bronchial responsiveness to histamine: relationship to the late asthmatic response and change in airway caliber. J Allergy Clin Immunol. 1982 Sep;70(3):170–177. doi: 10.1016/0091-6749(82)90038-0. [DOI] [PubMed] [Google Scholar]
- Casals-Stenzel J., Muacevic G., Weber K. H. Pharmacological actions of WEB 2086, a new specific antagonist of platelet activating factor. J Pharmacol Exp Ther. 1987 Jun;241(3):974–981. [PubMed] [Google Scholar]
- Chan-Yeung M., Lam S., Chan H., Tse K. S., Salari H. The release of platelet-activating factor into plasma during allergen-induced bronchoconstriction. J Allergy Clin Immunol. 1991 Mar;87(3):667–673. doi: 10.1016/0091-6749(91)90386-3. [DOI] [PubMed] [Google Scholar]
- Chung K. F., Barnes P. J. Effects of platelet activating factor on airway calibre, airway responsiveness, and circulating cells in asthmatic subjects. Thorax. 1989 Feb;44(2):108–115. doi: 10.1136/thx.44.2.108. [DOI] [PMC free article] [PubMed] [Google Scholar]
- Cockcroft D. W., Killian D. N., Mellon J. J., Hargreave F. E. Bronchial reactivity to inhaled histamine: a method and clinical survey. Clin Allergy. 1977 May;7(3):235–243. doi: 10.1111/j.1365-2222.1977.tb01448.x. [DOI] [PubMed] [Google Scholar]
- Cockcroft D. W., Murdock K. Y., Kirby J., Hargreave F. Prediction of airway responsiveness to allergen from skin sensitivity to allergen and airway responsiveness to histamine. Am Rev Respir Dis. 1987 Jan;135(1):264–267. doi: 10.1164/arrd.1987.135.1.264. [DOI] [PubMed] [Google Scholar]
- Cockcroft D. W., Ruffin R. E., Dolovich J., Hargreave F. E. Allergen-induced increase in non-allergic bronchial reactivity. Clin Allergy. 1977 Nov;7(6):503–513. doi: 10.1111/j.1365-2222.1977.tb01481.x. [DOI] [PubMed] [Google Scholar]
- Cuss F. M., Dixon C. M., Barnes P. J. Effects of inhaled platelet activating factor on pulmonary function and bronchial responsiveness in man. Lancet. 1986 Jul 26;2(8500):189–192. doi: 10.1016/s0140-6736(86)92489-x. [DOI] [PubMed] [Google Scholar]
- De Monchy J. G., Kauffman H. F., Venge P., Koëter G. H., Jansen H. M., Sluiter H. J., De Vries K. Bronchoalveolar eosinophilia during allergen-induced late asthmatic reactions. Am Rev Respir Dis. 1985 Mar;131(3):373–376. doi: 10.1164/arrd.1985.131.3.373. [DOI] [PubMed] [Google Scholar]
- Johnson P. R., Armour C. L., Black J. L. The action of platelet activating factor and its antagonism by WEB 2086 on human isolated airways. Eur Respir J. 1990 Jan;3(1):55–60. [PubMed] [Google Scholar]
- Keyzer J. J., Kauffman H. F., de Monchy J. G., Keyzer-Udding J. J., de Vries K. Urinary N tau-methylhistamine during early and late allergen-induced bronchial-obstructive reactions. J Allergy Clin Immunol. 1984 Sep;74(3 Pt 1):240–245. doi: 10.1016/0091-6749(84)90252-5. [DOI] [PubMed] [Google Scholar]
- Lai C. K., Jenkins J. R., Polosa R., Holgate S. T. Inhaled PAF fails to induce airway hyperresponsiveness to methacholine in normal human subjects. J Appl Physiol (1985) 1990 Mar;68(3):919–926. doi: 10.1152/jappl.1990.68.3.919. [DOI] [PubMed] [Google Scholar]
- Manning P. J., Rokach J., Malo J. L., Ethier D., Cartier A., Girard Y., Charleson S., O'Byrne P. M. Urinary leukotriene E4 levels during early and late asthmatic responses. J Allergy Clin Immunol. 1990 Aug;86(2):211–220. doi: 10.1016/s0091-6749(05)80068-5. [DOI] [PubMed] [Google Scholar]
- Manning P. J., Stevens W. H., Cockcroft D. W., O'Byrne P. M. The role of thromboxane in allergen-induced asthmatic responses. Eur Respir J. 1991 Jun;4(6):667–672. [PubMed] [Google Scholar]
- Morris J. F., Koski A., Johnson L. C. Spirometric standards for healthy nonsmoking adults. Am Rev Respir Dis. 1971 Jan;103(1):57–67. doi: 10.1164/arrd.1971.103.1.57. [DOI] [PubMed] [Google Scholar]
- O'Byrne P. M., Dolovich J., Hargreave F. E. Late asthmatic responses. Am Rev Respir Dis. 1987 Sep;136(3):740–751. doi: 10.1164/ajrccm/136.3.740. [DOI] [PubMed] [Google Scholar]
- Smith L. J., Rubin A. H., Patterson R. Mechanism of platelet activating factor-induced bronchoconstriction in humans. Am Rev Respir Dis. 1988 May;137(5):1015–1019. doi: 10.1164/ajrccm/137.5.1015. [DOI] [PubMed] [Google Scholar]
- Taylor G. W., Taylor I., Black P., Maltby N. H., Turner N., Fuller R. W., Dollery C. T. Urinary leukotriene E4 after antigen challenge and in acute asthma and allergic rhinitis. Lancet. 1989 Mar 18;1(8638):584–588. doi: 10.1016/s0140-6736(89)91611-5. [DOI] [PubMed] [Google Scholar]